11/3/2026

speaker
Jenny
Conference Operator

Good morning, my name is Jenny and I will be your conference operator today. At this time, I would like to welcome everyone to the Sophia Genetics third quarter 2026 earnings conference call. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. I would now like to turn the conference call over to Kellen Sanger, Sophia Genetics Head of Strategy. You may begin.

speaker
Kellen Sanger
Head of Strategy, SOPHiA GENETICS

Thank you, and good morning, everyone. Welcome to the Sophia Genetics Third Quarter 2026 Earnings Conference Call. Joining me today to discuss the results are Ross, our Chief Executive Officer, and George Cardoza, our Chief Financial Officer. I'd like to remind you that management will make statements during this call that are forward-looking statements within the meetings of federal securities laws. Thank you for your time today. During this call, we will present both IFRS and non-IFRS financial measures. A reconciliation of IFRS and non-IFRS measures is included in today's earnings press release, which is available on our website. With that, I'll now turn the call over to Ross.

speaker
Ross Muken
Chief Executive Officer, SOPHiA GENETICS

Thanks, Kellen, and good morning, everyone. Q3 was another strong quarter for Sophia. We delivered 25% year-over-year revenue growth as demand for our platform continues to expand. Growth in the U.S. market remained robust. New products in liquid biopsy and solid tumor continue to gain adoption. And new biopharma collaborations are establishing Sophia as a trailblazer in bringing clinical intelligence to patients around the globe. In addition to the strong growth, we also improved adjusted EBITDA materially in the third quarter by again dropping nearly 60% of our incremental revenue growth down to the bottom line. Bringing us closer to profitability. Today I'll update you on each of these areas and provide more details on the exciting path ahead. The field was founded with a vision to transform the world's healthcare data into actionable clinical intelligence for providers and patients. We started in genomics where we've established ourselves as one of the largest diagnostic companies in the world. In Q3, the Sophia Network performed 118,000 analysis on our platform, up 19% since last year. In other words, we analyzed roughly 40,000 patients per month across a network that spans 75 countries and 551 connected institutions globally. That network and the data flowing through it has allowed us to build one of the most sophisticated intelligence engines in healthcare. Every analysis run on our platform teaches our AI something new. It learns from a real-time, real-world data set that is unmatched in its breadth and diversity, including thousands of clinical contacts from patients in over 75 countries. and the learning doesn't stop with the data. Every day, pathologists, oncologists and scientists across our community review insights, flag cases and feed their expertise back into the platform. The result is something no institution could build on its own. We call it collective intelligence. Over the last several months, demand for our intelligence tools has been accelerating. Today, I'll touch briefly on two areas where we're seeing outsized growth, the U.S. market and liquid biopsy. In Q3, we delivered 41% revenue growth in the U.S. market. The growth has been especially impressive given the scale of our U.S. business, which is now our largest market globally. And based on the strong demand we're seeing, that growth is well positioned to continue. Recently signed major accounts, including North York, iGenomics, and a major West Coast health system, are scheduled to ramp significantly in the fourth quarter and into 2027. New signings also remain strong. In Q3 alone, we signed Path Group, one of the largest physician-led pathology providers in the U.S., to solid tumor and hemog applications. We also signed the University of Arkansas, the state's only health sciences university, for hemog. Beyond landing new accounts, our expand engine was strong as well. In Q3, the University of North Carolina Medical Center, a long-standing partner of Sophia, added additional applications across hematoma, hereditary cancer, and rare disorder testing. These wins, along with our strong momentum in the U.S., reflect a broader trend. Over the past 12 months, we've seen an inflection in U.S. growth. Reimbursement rates are rising, denial rates are improving, and sequencing costs continue to drop. These dynamics have created favorable economic conditions for hospitals and labs to launch their own testing capabilities. Large central labs have proven that genomic testing is highly profitable, and now providers want to participate. SOPHIA makes that possible. They enable institutions to launch their own testing in-house. We also empower institutions to retain control of their patient data, an increasingly valuable asset in the care ecosystem. Together, these trends are driving significant demand for our platform in the U.S. and beyond as institutions look for intelligence tools to help them transform their data into actionable insights while also driving beneficial economics. The second major growth driver in third quarter was new products. Bringing compelling products to our customers is critical for the widespread adoption of our platform. However, building products and working labs across the globe is not easy. In 2023, we launched a revolutionary new liquid biopsy test, MSK Access, which allows any institution in the world to bring liquid biopsy testing to their institutions. Making this test perform reliably required innovative new AI techniques to ensure accuracy and consistency. That investment is now paying off. In Q3, we performed 4,200 liquid biopsy analysis globally, up more than 100% year on year and 41% sequentially versus Q2 levels. Looking ahead, we expect the liquid biopsy business to continue ramping, offering a meaningful catalyst for future growth. Today, we have signed more than 85 institutions to the application, including six in the third quarter alone. Of these new signings, a large number are currently implementing the platform and ramping usage. Unlike the U.S., liquid biopsy is an emerging technology in the rest of the world. As a leader in liquid biopsy outside of the U.S., Sophia and its growing network are well-positioned to capture this growth as adoption increases. To accelerate the ex-U.S. adoption trend, we are making a series of strategic investments. This includes adding a new medical affairs function focused on generating evidence, demonstrating clinical utility, and advocating for the adoption of liquid biopsy testing across Europe, Asia, and Latin America. I look forward to sharing more on the team's progress and the growing demand for liquid biopsy in the quarters ahead. As our genomics footprint continues to expand and our network becomes larger, biopharma companies increasingly have come to recognize the value of our unique global reach and the data being streamed through our platform. This has resulted in a series of large signings with biopharma over the past nine months. covering areas such as patient selection and stratification, companion diagnostics, foundational model building, real-world evidence, and the sponsored deployment of our tests. This quarter, I'm proud to announce that the success is continuing. During the quarter, we signed a major new collaboration with a top 10 biopharma company to develop a multimodal AI predictor to help identify which bladder cancer patients are most likely to benefit from immunotherapy. The project leverages Sophia's deep expertise in clinical intelligence as well as our proprietary data to build two complementary predictive models aimed at understanding patient response to a targeted therapy. Congratulations to the team on this win. This new business builds on the progress discussed last quarter when we announced the signing of not one but two diagnostic programs with AstraZeneca, the first in Sophia's history. The first CDX program aims to develop a key solid tumor application into a decentralized companion diagnostic for patients with prostate cancer. We announced additional details on this program last month, including that the test will incorporate Myriad Genetics' novel prostate cancer-specific genomic instability score capability into the technology. The second CDX program will leverage a hematological oncology application to support a therapy for patients with blood cancer. Together, these CDXs demonstrate the value of SOPHIA's network. For biopharma, the hardest part of a companion diagnostic is improving the biomarker works. It's getting the test to patients who need it. Everywhere they are, at the moment, a treatment decision is being made. And that's the problem Sophia was built to solve. Our platform already fits inside hundreds of hospitals and laboratories across more than 70 countries. Analyzing genomic data locally and consistently. This means that a CDX developed with us doesn't depend on shipping samples to a single central lab or waiting weeks for a result. It launches where oncologists are already working. Because the same platform brings together genomic, radiomic, and clinical data on one patient, you aren't limited to a single analyte test. You can build software as a medical device that reflects how disease actually behaves across modalities and over time refine it as real-world evidence that flows back from the same network. The result is a diagnostic that reaches more patients faster, generates evidence continuously, and travels with your therapy into every market you enter. That is what clinical intelligence means in practice, and it is why partners who want their drugs to reach the right patient on day one are choosing to build with Sophia. To conclude, our commercial momentum keeps building. New geographies, exciting new products, and expanded relationships with biopharma offer meaningful catalysts for future growth. Given these factors, along with the dynamics we are seeing in our end markets, we now expect our full year 2026 revenue to be at the upper end of the previously issued guidance range of $94 million to $96 million. The updated outlook reflects strong business performance partially offset by the impact of foreign exchange. Furthermore, as we continue to grow, it is critical that we do so in a sustainable way. In the third quarter, we improved adjusted EBITDA by an impressive 31% year-over-year, dropping nearly 60% of our incremental revenue down to the bottom line. This performance represents the natural operating leverage of our business. Our tech-first, AI-native approach, built on a highly efficient intelligence platform, scales quickly without a proportional increase in cost. We remain fully committed to profitable growth. As previously stated, we expect to keep converting growth into further improvement in adjusted EBITDA in the fourth quarter and to cross over to positive adjusted EBITDA in the second half of next year. Underneath it all is a growing network of institutions relying on Sophia to turn complex data into clinical intelligence. The more data that flows through our platform, the smarter it gets, and the more value we deliver to our customers. With that, I'll turn the call over to George, who will take you through the results in more detail.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation